Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

FDA grants priority review to Daiichi Sankyo & Merck’s lung cancer drug application

The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck

New guidance aims to speed up diagnosis of childhood abdominal cancers

Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial

Highlights Mirvetuximab-based regimen promise

University of Leeds launches landmark HALO study on lifelong impact of childhood blood disorders

Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy